LTPA2018008I1 - Kristalai - Google Patents
KristalaiInfo
- Publication number
- LTPA2018008I1 LTPA2018008I1 LTPA2018008C LTPA2018008C LTPA2018008I1 LT PA2018008 I1 LTPA2018008 I1 LT PA2018008I1 LT PA2018008 C LTPA2018008 C LT PA2018008C LT PA2018008 C LTPA2018008 C LT PA2018008C LT PA2018008 I1 LTPA2018008 I1 LT PA2018008I1
- Authority
- LT
- Lithuania
- Prior art keywords
- crystals
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
- C07D241/22—Benzenesulfonamido pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009151727 | 2009-06-26 | ||
| JP2009151728 | 2009-06-26 | ||
| JP2009151729 | 2009-06-26 | ||
| PCT/JP2010/060798 WO2010150865A1 (ja) | 2009-06-26 | 2010-06-25 | 結晶 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LTPA2018008I1 true LTPA2018008I1 (lt) | 2018-05-10 |
| LTC2447254I2 LTC2447254I2 (lt) | 2022-04-25 |
Family
ID=43386634
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP17186415.0T LT3275871T (lt) | 2009-06-26 | 2010-06-25 | Kristalai |
| LTEP10792183.5T LT2447254T (lt) | 2009-06-26 | 2010-06-25 | Kristalai |
| LTPA2018008C LTC2447254I2 (lt) | 2009-06-26 | 2018-04-18 | Kristalai |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP17186415.0T LT3275871T (lt) | 2009-06-26 | 2010-06-25 | Kristalai |
| LTEP10792183.5T LT2447254T (lt) | 2009-06-26 | 2010-06-25 | Kristalai |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US8791122B2 (lt) |
| EP (3) | EP3689855A1 (lt) |
| JP (1) | JPWO2010150865A1 (lt) |
| KR (4) | KR102705198B1 (lt) |
| CN (2) | CN104326991A (lt) |
| AR (1) | AR077242A1 (lt) |
| AU (1) | AU2010263569B2 (lt) |
| BR (2) | BRPI1015936B1 (lt) |
| CA (1) | CA2764475C (lt) |
| CL (1) | CL2011003264A1 (lt) |
| CO (1) | CO6430432A2 (lt) |
| CY (3) | CY1119788T1 (lt) |
| DK (2) | DK2447254T3 (lt) |
| ES (2) | ES2660007T3 (lt) |
| HK (1) | HK1244788A1 (lt) |
| HR (2) | HRP20180171T1 (lt) |
| HU (3) | HUE048467T2 (lt) |
| IL (3) | IL216928A (lt) |
| LT (3) | LT3275871T (lt) |
| MA (1) | MA33637B1 (lt) |
| MX (2) | MX346318B (lt) |
| MY (1) | MY186531A (lt) |
| NO (2) | NO2447254T3 (lt) |
| NZ (1) | NZ597352A (lt) |
| PH (2) | PH12015502824A1 (lt) |
| PL (2) | PL2447254T3 (lt) |
| PT (2) | PT2447254T (lt) |
| RU (1) | RU2556206C3 (lt) |
| SG (2) | SG176915A1 (lt) |
| SI (2) | SI3275871T1 (lt) |
| TW (1) | TWI531565B (lt) |
| WO (1) | WO2010150865A1 (lt) |
| ZA (1) | ZA201109099B (lt) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2246336T3 (da) * | 2008-02-28 | 2020-07-20 | Nippon Shinyaku Co Ltd | Fibroseinhibitor |
| MY163762A (en) | 2008-07-23 | 2017-10-31 | Toray Industries | Therapeutic agent for chronic renal failure |
| CN106279047B (zh) | 2015-05-13 | 2019-05-03 | 普济生物科技（台州）有限公司 | 一种前列环素受体激动剂的制备方法 |
| WO2016193994A1 (en) | 2015-05-29 | 2016-12-08 | Megafine Pharma (P) Ltd. | Amorphous selexipag and process for preparation thereof |
| WO2017029594A1 (en) * | 2015-08-17 | 2017-02-23 | Dr. Reddy's Laboratories Limited | Processes for preparation of selexipag and its amorphous form |
| EP3344607B1 (en) | 2015-09-03 | 2019-11-06 | Teva Pharmaceuticals International GmbH | Solid state forms of selexipag |
| WO2017042731A1 (en) | 2015-09-10 | 2017-03-16 | Lupin Limited | Amorphous form of selexipag and solid dispersion thereof |
| WO2017042828A2 (en) * | 2015-09-10 | 2017-03-16 | Megafine Pharma (P) Ltd. | Process for the preparation of selexipag and intermediates thereof |
| AU2016366073B2 (en) * | 2015-12-02 | 2021-08-26 | Nippon Shinyaku Co., Ltd. | Pharmaceutical composition containing 2-{4-[N-(5,6- diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N- (methylsulfonyl)acetamide |
| WO2017109772A1 (en) * | 2015-12-20 | 2017-06-29 | Mapi Pharma Ltd. | Amorphous form of selexipag |
| EP3192502A1 (en) | 2016-01-15 | 2017-07-19 | Sandoz Ag | Pharmaceutical composition of selexipag |
| ES2911531T3 (es) | 2016-04-01 | 2022-05-19 | Honour R&D | Procedimiento para la preparación de los derivados de difenilpirazina |
| CN105949135A (zh) * | 2016-05-10 | 2016-09-21 | 湖南欧亚生物有限公司 | 一种赛乐西帕的合成方法 |
| EP3481807A4 (en) * | 2016-07-05 | 2020-01-15 | Maithri Drugs Private Limited | NEW PROCESS FOR THE PREPARATION OF 2- {4 - [(5,6-DIPHENYL PYRAZIN-2-YL) (ISOPROPYL) AMINO] BUTOXY} -N- (METHYLSULFONYL) ACETAMIDE AND NEW POLYMORPHS THEREOF |
| WO2018015974A1 (en) | 2016-07-20 | 2018-01-25 | Mylan Laboratories Limited | Polymorphic forms and amorphous solid dispersion of selexipag |
| WO2018022704A1 (en) | 2016-07-26 | 2018-02-01 | Teva Pharmaceuticals International Gmbh | Crystalline form vi of selexipag |
| WO2018078383A1 (en) | 2016-10-27 | 2018-05-03 | Cipla Limited | Pharmaceutical composition comprising amorphous selexipag |
| CN108069914A (zh) * | 2016-11-17 | 2018-05-25 | 江苏艾立康药业股份有限公司 | 一种西里帕格晶型的制备方法 |
| CA3046025A1 (en) | 2016-12-14 | 2018-06-21 | Respira Therapeutics, Inc. | Methods and compositions for treatment of pulmonary hypertension and other lung disorders |
| EP3335699A1 (en) | 2016-12-15 | 2018-06-20 | H e x a l Aktiengesellschaft | Selexipag formulation in liquisolid system |
| JOP20190204A1 (ar) | 2017-03-08 | 2019-09-05 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على سيليكسيباغ |
| EP3658187A1 (en) | 2017-07-27 | 2020-06-03 | Allergan, Inc. | Prostacyclin receptor agonists for reduction of body fat |
| TWI801421B (zh) | 2017-09-28 | 2023-05-11 | 日商日本新藥股份有限公司 | 結晶 |
| BR112020008940A2 (pt) | 2017-11-16 | 2020-10-20 | Nippon Shinyaku Co., Ltd. | preparação de liberação controlada |
| US10407396B2 (en) | 2017-11-16 | 2019-09-10 | Apotex Inc. | Crystalline form of selexipag |
| JP2021512902A (ja) | 2018-02-07 | 2021-05-20 | メッドシャイン ディスカバリー インコーポレイテッド | プロスタサイクリン受容体アゴニスト |
| US20200397700A1 (en) * | 2018-02-21 | 2020-12-24 | Nippon Shinyaku Co., Ltd. | Granular composition, production method for granular composition, and dissolution property improvement method for granular composition |
| CN109125325B (zh) | 2018-09-25 | 2021-05-25 | 中国人民解放军总医院 | 前列环素受体激动剂的医药用途 |
| EP3705115B1 (en) | 2019-03-07 | 2021-06-30 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Composition containing selexipag |
| JP2022532076A (ja) | 2019-05-06 | 2022-07-13 | アクテリオン ファーマシューティカルズ リミテッド | サルコイドーシス関連肺高血圧症の治療方法 |
| JP2022533394A (ja) | 2019-05-21 | 2022-07-22 | アクテリオン ファーマシューティカルズ リミテッド | 肺動脈性肺高血圧症の治療を受けている患者のセレキシパグへの移行方法 |
| US20220323437A1 (en) | 2019-06-11 | 2022-10-13 | Actelion Pharmaceuticals Ltd | Methods for treating pulmonary arterial hypertension |
| WO2021023271A1 (zh) * | 2019-08-06 | 2021-02-11 | 南京明德新药研发有限公司 | 作为前列环素受体激动剂的化合物的晶型及其制备方法 |
| CA3154802A1 (en) | 2019-10-23 | 2021-04-29 | Marc Patrik SCHRADER | Pharmaceutical composition comprising selexipag |
| JP2023504115A (ja) | 2019-11-29 | 2023-02-01 | アクテリオン ファーマシューティカルズ リミテッド | 肺動脈性肺高血圧症の治療方法 |
| JP2023507626A (ja) | 2019-12-16 | 2023-02-24 | テナックス・セラピューティクス，インコーポレイテッド | 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン |
| WO2021152060A1 (en) | 2020-01-31 | 2021-08-05 | Actelion Pharmaceuticals Ltd | Controlled release selexipag composition |
| EP4100013A1 (en) | 2020-02-03 | 2022-12-14 | Actelion Pharmaceuticals Ltd | Methods of treating and assessing pulmonary arterial hypertension with selexipag |
| CN112500358B (zh) * | 2020-11-18 | 2022-03-15 | 江苏豪森药业集团有限公司 | 赛乐西帕晶型及其制备方法 |
| WO2022106621A1 (en) | 2020-11-20 | 2022-05-27 | Actelion Pharmaceuticals Ltd | Selexipag for use via intracolonic administration |
| TW202239408A (zh) | 2021-01-29 | 2022-10-16 | 瑞士商艾克泰聯製藥有限公司 | 包含二苯基吡𠯤衍生物的醫藥組成物 |
| TW202241425A (zh) | 2021-01-29 | 2022-11-01 | 瑞士商艾克泰聯製藥有限公司 | 用於製造二苯基吡𠯤衍生物之程序 |
| WO2022238375A1 (en) | 2021-05-11 | 2022-11-17 | Actelion Pharmaceuticals Ltd | Methods of treating pulmonary hypertension |
| WO2023131608A1 (en) | 2022-01-04 | 2023-07-13 | Actelion Pharmaceuticals Ltd | Controlled release compositions |
| WO2023214059A1 (en) | 2022-05-06 | 2023-11-09 | Actelion Pharmaceuticals Ltd | Diphenylpyrazine compounds as prodrugs |
| WO2024017964A1 (en) | 2022-07-20 | 2024-01-25 | Actelion Pharmaceuticals Ltd | Injectable pharmaceutical composition comprising a diphenylpyrazine derivative |
| WO2024133620A1 (en) | 2022-12-22 | 2024-06-27 | Actelion Pharmaceuticals Ltd | In vitro dissolution test |
| WO2024142718A1 (ja) * | 2022-12-27 | 2024-07-04 | 株式会社トクヤマ | セレキシパグのｉ型結晶の製造方法 |
| EP4393474A1 (en) * | 2022-12-28 | 2024-07-03 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A formulation comprising selexipag |
| EP4393476A1 (en) * | 2022-12-28 | 2024-07-03 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A tablet formulation comprising selexipag |
| EP4393475A1 (en) | 2022-12-28 | 2024-07-03 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Formulations comprising selexipag |
| WO2024194449A1 (en) | 2023-03-23 | 2024-09-26 | Actelion Pharmaceuticals Ltd | Pharmaceutical composition comprising a diphenylpyrazine derivative |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030092760A1 (en) | 2001-03-12 | 2003-05-15 | Toray Industries, Inc. | Therapeutic agent for renal failure |
| EP1106176B1 (en) | 1999-05-10 | 2008-06-18 | Toray Industries, Inc. | Remedies for renal failure |
| DE60102106T2 (de) | 2000-08-03 | 2004-07-15 | Pfizer Products Inc., Groton | Diazacyclooctanverbindungen und ihre therapeutische Verwendung |
| WO2002085412A1 (fr) * | 2001-04-18 | 2002-10-31 | Fujisawa Pharmaceutical Co., Ltd. | Inhibiteurs de la fibrose des tissus |
| TWI316055B (lt) | 2001-04-26 | 2009-10-21 | Nippon Shinyaku Co Ltd | |
| EP1642584A1 (en) | 2003-06-25 | 2006-04-05 | Cardiovascular Institute, Ltd | External preparation for improving coital function |
| US7112393B2 (en) | 2003-07-29 | 2006-09-26 | Canon Kabushiki Kaisha | Non-magnetic toner |
| DK2246336T3 (da) | 2008-02-28 | 2020-07-20 | Nippon Shinyaku Co Ltd | Fibroseinhibitor |
| WO2009154246A1 (ja) | 2008-06-19 | 2009-12-23 | 日本新薬株式会社 | 勃起不全治療剤 |
| WO2009157396A1 (ja) | 2008-06-23 | 2009-12-30 | 日本新薬株式会社 | 脊柱管狭窄症治療剤 |
| CN102065864B (zh) | 2008-06-23 | 2012-11-21 | 日本新药株式会社 | 炎性肠病治疗剂 |
| WO2009157397A1 (ja) | 2008-06-23 | 2009-12-30 | 日本新薬株式会社 | 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤 |
| MY163762A (en) | 2008-07-23 | 2017-10-31 | Toray Industries | Therapeutic agent for chronic renal failure |
| BRPI0918134B1 (pt) | 2008-09-10 | 2019-02-12 | Kaken Pharmaceutical Co., Ltd | Derivado de prostaglandina i2 |
-
2010
- 2010-06-25 KR KR1020247016901A patent/KR102705198B1/ko active IP Right Grant
- 2010-06-25 KR KR1020127000526A patent/KR102669213B1/ko active IP Right Grant
- 2010-06-25 HU HUE17186415A patent/HUE048467T2/hu unknown
- 2010-06-25 TW TW099120927A patent/TWI531565B/zh active
- 2010-06-25 MY MYPI2011006259A patent/MY186531A/en unknown
- 2010-06-25 WO PCT/JP2010/060798 patent/WO2010150865A1/ja active Application Filing
- 2010-06-25 EP EP19219098.1A patent/EP3689855A1/en active Pending
- 2010-06-25 CA CA2764475A patent/CA2764475C/en active Active
- 2010-06-25 RU RU2012102678A patent/RU2556206C3/ru active Protection Beyond IP Right Term
- 2010-06-25 HU HUE10792183A patent/HUE036721T2/hu unknown
- 2010-06-25 CN CN201410524475.0A patent/CN104326991A/zh active Pending
- 2010-06-25 BR BRPI1015936-3A patent/BRPI1015936B1/pt active IP Right Grant
- 2010-06-25 US US13/379,531 patent/US8791122B2/en active Active
- 2010-06-25 NZ NZ597352A patent/NZ597352A/xx unknown
- 2010-06-25 PL PL10792183T patent/PL2447254T3/pl unknown
- 2010-06-25 JP JP2011519943A patent/JPWO2010150865A1/ja active Pending
- 2010-06-25 PT PT107921835T patent/PT2447254T/pt unknown
- 2010-06-25 KR KR1020247016902A patent/KR20240090717A/ko not_active Application Discontinuation
- 2010-06-25 ES ES10792183.5T patent/ES2660007T3/es active Active
- 2010-06-25 NO NO10792183A patent/NO2447254T3/no unknown
- 2010-06-25 SI SI201031997T patent/SI3275871T1/sl unknown
- 2010-06-25 LT LTEP17186415.0T patent/LT3275871T/lt unknown
- 2010-06-25 SI SI201031634T patent/SI2447254T1/en unknown
- 2010-06-25 AU AU2010263569A patent/AU2010263569B2/en active Active
- 2010-06-25 MX MX2015003876A patent/MX346318B/es unknown
- 2010-06-25 EP EP17186415.0A patent/EP3275871B1/en not_active Revoked
- 2010-06-25 SG SG2011094083A patent/SG176915A1/en unknown
- 2010-06-25 SG SG10201403313WA patent/SG10201403313WA/en unknown
- 2010-06-25 DK DK10792183.5T patent/DK2447254T3/en active
- 2010-06-25 PT PT171864150T patent/PT3275871T/pt unknown
- 2010-06-25 EP EP10792183.5A patent/EP2447254B1/en active Active
- 2010-06-25 AR ARP100102270A patent/AR077242A1/es not_active Application Discontinuation
- 2010-06-25 PL PL17186415T patent/PL3275871T3/pl unknown
- 2010-06-25 ES ES17186415T patent/ES2797124T3/es active Active
- 2010-06-25 MX MX2011013471A patent/MX2011013471A/es active IP Right Grant
- 2010-06-25 LT LTEP10792183.5T patent/LT2447254T/lt unknown
- 2010-06-25 BR BR122021005510-6A patent/BR122021005510B1/pt not_active IP Right Cessation
- 2010-06-25 CN CN201080028176.8A patent/CN102459198B/zh active Active
- 2010-06-25 KR KR1020177005424A patent/KR20170024165A/ko not_active Application Discontinuation
- 2010-06-25 DK DK17186415.0T patent/DK3275871T3/da active
-
2011
- 2011-12-09 ZA ZA2011/09099A patent/ZA201109099B/en unknown
- 2011-12-13 IL IL216928A patent/IL216928A/en active IP Right Grant
- 2011-12-22 CL CL2011003264A patent/CL2011003264A1/es unknown
- 2011-12-26 CO CO11178426A patent/CO6430432A2/es not_active Application Discontinuation
-
2012
- 2012-01-20 MA MA34554A patent/MA33637B1/fr unknown
- 2012-06-21 HK HK18103192.0A patent/HK1244788A1/zh unknown
-
2014
- 2014-01-22 US US14/160,641 patent/US9284280B2/en active Active
- 2014-01-22 US US14/160,699 patent/US9340516B2/en active Active
-
2015
- 2015-06-09 US US14/734,012 patent/US9440931B2/en active Active
- 2015-12-18 PH PH12015502824A patent/PH12015502824A1/en unknown
- 2015-12-18 PH PH12015502825A patent/PH12015502825A1/en unknown
- 2015-12-27 IL IL243287A patent/IL243287B/en active IP Right Grant
- 2015-12-27 IL IL243293A patent/IL243293A0/en unknown
-
2018
- 2018-01-18 CY CY20181100063T patent/CY1119788T1/el unknown
- 2018-01-30 HR HRP20180171TT patent/HRP20180171T1/hr unknown
- 2018-04-11 HU HUS1800015C patent/HUS1800015I1/hu unknown
- 2018-04-11 CY CY2018011C patent/CY2018011I2/el unknown
- 2018-04-18 LT LTPA2018008C patent/LTC2447254I2/lt unknown
- 2018-04-23 NO NO2018015C patent/NO2018015I1/no unknown
-
2020
- 2020-04-02 HR HRP20200539TT patent/HRP20200539T1/hr unknown
- 2020-04-03 CY CY20201100317T patent/CY1122893T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTPA2018008I1 (lt) | Kristalai | |
| BRPI1008774A2 (pt) | espiroamida substituída | |
| DE112010004215A5 (de) | Hydrostataktor | |
| DE112010002949A5 (de) | Kupplungstastpunkte | |
| DK2411442T4 (da) | Umættet polyesterresin | |
| DK2430035T3 (da) | Uracylspipooxetannukleosider | |
| BRPI1008827A2 (pt) | deisobutenizador | |
| DE112010002728A5 (de) | Turboinhalator | |
| DE112010004249A5 (de) | Spindelaktor | |
| DE112009005323A5 (de) | Hebelarmprüfmaschine | |
| DE112009005462T8 (de) | Lenkungsssteuervorrichtung | |
| BRPI1008070A2 (pt) | tricianoboratos | |
| DK2483126T3 (da) | Skinnekøretøj | |
| DK2506968T3 (da) | Faujasit-zeolit | |
| DE112010004865T8 (de) | Lamellennassreibkupplung | |
| DE112010003255A5 (de) | Fördergutverteiler | |
| BRPI1010159A2 (pt) | bistuti | |
| DE602010000025D1 (de) | Fahrzeugsitzgurtvorrichtung | |
| FI20090100A0 (fi) | Biotinidaasimääritys | |
| DE112010002351A5 (de) | Klemmorrichtung | |
| DE112010003843T8 (de) | Lastansteuervorrichtung | |
| DE202009005065U8 (de) | Kartonverschließmaschine | |
| DE102009034429A8 (de) | Flachantenne | |
| DE112010004370A5 (de) | Solarkollektorsystern | |
| ES1071436Y (es) | Marquesina autoportante |